TETLOW SHARON 4

What Happened
Sharon Tetlow, a director of Structure Therapeutics Inc. (GPCR), was granted 39,453 derivative shares (equity award/option-like instrument) on 2026-06-17. The Form 4 reports an acquisition at $0.00 per share (total reported value $0) because the instrument is a derivative; the filing notes the option exercise price per share equals the fair market value of an Ordinary Share on the grant date based on the trading price of the Issuer’s ADSs. This is an award/grant (not a sale) and does not reflect an immediate cash purchase or disposition.

Key Details

• Transaction date: 2026-06-17; Form 4 filed 2026-06-18 (timely).
• Reported transaction: Grant/Award of 39,453 derivative shares at $0.00 (transaction code A, derivative security).
• Vesting: Shares vest in equal monthly installments over the 12 months following June 17, 2026; fully vested no later than the day before the Issuer’s 2027 annual meeting.
• ADS conversion: Ordinary Shares may be represented by ADSs; each ADS = 3 Ordinary Shares (may affect public ADS reporting vs. Ordinary Share counts).
• Shares owned after transaction: Not specified on the filing.
• Filing status: Timely (no late-filing indication).

Context
This is an equity compensation grant to a director — a common form of non-cash compensation and corporate governance alignment, rather than a market buy or sell. The exercise price is set equal to fair market value at grant (per footnote), so there would typically be no intrinsic gain at grant unless the stock price rises thereafter. No immediate sale or cashless exercise was reported.